Early Drug Development

Supporting Lead Optimization and Preclinical Candidate Selection

Early drug development requires integration of ADME/DMPK profiling, chemistry support, pharmacological validation, and toxicology assessment to progress lead compounds toward preclinical candidate nomination. Biotts provides pharmaceutical and biotech partners with laboratory capabilities and study coordination designed to generate decision-ready data packages that inform compound selection, dose selection, and regulatory strategy at the preclinical stage.

Our approach centers on structured workflows with defined study objectives, appropriate controls, and transparent reporting. Studies are designed to answer specific questions – pharmacokinetic behavior, target engagement, safety signals, metabolic stability – rather than generate data for data’s sake. Results are delivered with scientific interpretation that supports internal go/no-go decisions and enables productive regulatory interactions (e.g., FDA pre-IND consultations, EMA scientific advice).